ProKidney
PROK

ProKidney (PROK) analyst forecast and price target

Analyst forecast

Buy

Consensus of 7 analyst ratings

Buy
4
Hold
2
Sell
1

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$12.00May 18, 2026
HC Wainwright & Co.Initiated CoverageBuy$12.00Dec 16, 2025
UBSMaintainedBuy$8.00 from $4.00Jul 15, 2025
GuggenheimMaintainedBuy$7.00 from $6.00Jul 14, 2025
CitigroupMaintainedBuy$9.00 from $6.00Jul 9, 2025
B of A SecuritiesDowngradedNeutral → Underperform$1.00 from $3.00Jun 30, 2025
JP MorganInitiated CoverageNeutralSep 30, 2024
GuggenheimInitiated CoverageBuy$6.00Sep 10, 2024
B of A SecuritiesMaintainedNeutral$3.00 from $4.00Sep 4, 2024
JefferiesMaintainedBuy$6.00 from $15.00Jun 10, 2024
B of A SecuritiesMaintainedNeutral$4.00 from $3.00May 29, 2024
Morgan StanleyInitiated CoverageEqual-Weight$3.00Mar 7, 2024
B of A SecuritiesDowngradedBuy → Neutral$2.00 from $8.00Jan 2, 2024
BTIGInitiated CoverageBuy$16.00Jul 25, 2023

Frequently asked questions

  • Is PROK a buy, sell, or hold?

    Analysts covering ProKidney currently average a Buy rating: 4 buy, 2 hold and 1 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.

  • What is the latest analyst rating on PROK?

    On May 18, 2026, HC Wainwright & Co. maintained ProKidney at Buy with a price target of $12.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.